Biotechnology core laboratories: An overview.

J Biomol Tech

Institute of Molecular Biology, University of Oregon, Eugene, OR 97403, USA.

Published: March 2000

An assessment of the capabilities of biotechnology core facilities requires access to current data on state-of-the-art technologies, personnel, space, services, financial issues, and the demand for such facilities. Data on these topics should be useful to researchers, facility personnel, administrators, and granting agencies.To obtain such data, the Association of Biomolecular Resource Facilities (ABRF) conducted a general survey on the operation and technical capabilities of core facilities. A total of 81 ABRF core laboratories voluntarily responded to the survey. Just over 60% of the respondents were from academic institutions, with the remaining located in research institutes, industry, and one U.S. government laboratory. Fifty laboratories provided financial data, with 47 of these operating on a nonprofit basis. Four laboratories were fully self-supporting from user fees.A typical facility had three full-time staff members and occupied approximately 1100 square feet (ft(2)). The most frequently offered services were N-terminal protein sequencing, protein fragmentation, peptide synthesis and purification, amino acid analysis, DNA synthesis, and DNA sequencing. One third of the facilities provided mass analysis by matrix-assisted laser desorption and ionization (MALDI) mass spectrometry, a recently introduced service that has been offered on an average for 3 years. Another relatively new service, bioinformatics support, is offered by about one third of the responding laboratories.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291618PMC

Publication Analysis

Top Keywords

biotechnology core
8
core laboratories
8
core facilities
8
laboratories
5
facilities
5
laboratories overview
4
overview assessment
4
assessment capabilities
4
capabilities biotechnology
4
facilities requires
4

Similar Publications

Guiding molecular assembly of peptides into rationally engineered nanostructures remains a major hurdle against the development of functional peptide-based nanomaterials. Various non-covalent interactions come into play to drive the formation and stabilization of these assemblies, of which electrostatic interactions are key. Here, the atomistic mechanisms by which electrostatic interactions contribute toward controlling self-assembly and lateral association of ultrashort β-sheet forming peptides are deciphered.

View Article and Find Full Text PDF

Expression and purification of Mycobacterium tuberculosis F-dependent glucose-6-phosphate dehydrogenase enzyme using Escherichia coli.

Protein Expr Purif

January 2025

Manchester Institute of Biotechnology, Department of Chemistry, University of Manchester, 131 Princess St, Manchester, M1 7DN, United Kingdom. Electronic address:

Since their discovery in Mycobacterium tuberculosis (Mtb), F-dependent enzymes have been identified as both important drug targets and potential industrial biocatalysts, including for bioremediation of otherwise recalcitrant substrates. Mtb-FGD1, utilizes glucose 6-phosphate (G6P) as an electron donor for the reduction of F. Current expression systems for Mtb-FGD1 use Mycobacterium smegmatis as host, because of the tendency for it to form inclusion bodies in E.

View Article and Find Full Text PDF

The Taiwan-ADNI workflow toward integrating plasma p-tau217 into prediction models for the risk of Alzheimer's disease and tau burden.

Alzheimers Dement

January 2025

Department of Neurology, Cognition and Aging Center, Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung City, Taiwan.

Introduction: We integrated plasma biomarkers from the Taiwan Alzheimer's Disease Neuroimaging Initiative and propose a workflow to identify individuals showing amyloid-positive positron emission tomography (PET) with low/intermediate tau burden based on [18F]Florzolotau PET-based quantification.

Methods: We assessed 361 participants across the Alzheimer's disease (AD) and non-AD continuum and measured plasma phosphorylated tau (p-tau)217, p-tau181, amyloid beta (Aβ)42/40 ratio, neurofilament light chain, and glial fibrillary acidic protein levels at two medical centers. We evaluated the diagnostic potential of these biomarkers.

View Article and Find Full Text PDF

Activatable multifunctional nanoparticles present considerable advantages in cancer treatment by integrating both diagnostic and therapeutic functionalities into a single platform. These nanoparticles can be precisely engineered to selectively target cancer cells, thereby reducing the risk of damage to healthy tissues. Once localized at the target site, they can be activated by external stimuli such as light, pH changes, or specific enzymes, enabling precise control over the release of therapeutic agents or the initiation of therapeutic effects.

View Article and Find Full Text PDF

The latest breakthroughs in information technology and biotechnology have catalyzed a revolutionary shift within the modern healthcare landscape, with notable impacts from artificial intelligence (AI) and deep learning (DL). Particularly noteworthy is the adept application of large language models (LLMs), which enable seamless and efficient communication between scientific researchers and AI systems. These models capitalize on neural network (NN) architectures that demonstrate proficiency in natural language processing, thereby enhancing interactions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!